## AMGN: Amgen Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.7% below STRENGTH zone (3.0-6.0%); PEG 1.01 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($322.39)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Is Now the Right Time to Revisit Amgen After Its Recent 18% Price Surge?**
- Source: Simply Wall Street | 20251130T042057 | Bullish | Relevance: 100%
- Amgen's stock has surged 18% in the last month, prompting a re-evaluation of its current valuation. A Discounted Cash Flow (DCF) analysis suggests Amgen (NASDAQ:AMGN) may be undervalued by 37.8%, with an intrinsic value of $555.10 per share. The article also discusses Amgen's PE ratio of 26.6x, which is above the industry average but below its peer group, and introduces "Narratives" as a tool for investors to customize their valuation outlook based on different scenarios for Amgen's future.

**2. Panagora Asset Management Inc. Has $136.94 Million Holdings in Amgen Inc. $AMGN**
- Source: MarketBeat | 20251201T124508 | Somewhat-Bullish | Relevance: 99%
- Panagora Asset Management Inc. significantly increased its stake in Amgen Inc. by 367.4% during the second quarter, holding 490,457 shares valued at $136.94 million. Other institutional investors also adjusted their positions, contributing to 76.50% institutional ownership of Amgen stock. The article details Amgen's recent earnings beat, dividend announcement, stock performance metrics, and recent analyst ratings and insider transactions.

**3. Groupama Asset Managment Sells 2,736 Shares of Amgen Inc. $AMGN**
- Source: MarketBeat | 20251129T113658 | Somewhat-Bullish | Relevance: 99%
- Groupama Asset Management significantly reduced its stake in Amgen Inc. by selling 2,736 shares, decreasing its holdings by 16.6%. This move comes alongside other institutional investors adjusting their positions and notable insider selling by Amgen executives. Despite the share reduction, Amgen reported strong quarterly earnings, exceeded revenue expectations, and announced a quarterly dividend, while analysts maintain a "Hold" rating with an average price target of $333.74.

**4. Legacy Capital Wealth Partners LLC Lowers Position in Amgen Inc. $AMGN**
- Source: MarketBeat | 20251130T122407 | Somewhat-Bullish | Relevance: 99%
- Legacy Capital Wealth Partners LLC significantly reduced its stake in Amgen Inc. by 41.5% in Q2, selling 1,160 shares and holding 1,636 shares valued at $457,000. Despite this, Amgen exceeded quarterly expectations with strong revenues and EPS, and analysts maintain a "Hold" consensus with an average target price of $333.74. The company also announced a quarterly dividend of $2.38.

**5. Berry Wealth Group LP Buys New Holdings in Amgen Inc. $AMGN**
- Source: MarketBeat | 20251129T083305 | Somewhat-Bullish | Relevance: 99%
- Berry Wealth Group LP has purchased a new position in Amgen Inc. by acquiring 865 shares valued at approximately $242,000 during the second quarter. Other institutional investors also significantly adjusted their holdings in Amgen, with notable increases from Laurel Wealth Advisors LLC, Norges Bank, Nuveen LLC, Vanguard Group Inc., and Charles Schwab Investment Management Inc. The article also provides an overview of recent analyst ratings, insider trading activities, and Amgen's financial performance and dividend announcements.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wells Fargo | $325 | $300 | +8% |
| 2025-12-03 | BMO Capital | $372 | $335 | +11% |
| 2025-11-14 | Piper Sandler | $381 | $342 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-03 | BMO Capital | main | Outperform |
| 2025-11-14 | Piper Sandler | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.00M) |
| Sells | 7 ($2.74M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.3%)
- Blackrock Inc.: 8.6% (-1.2%)
- State Street Corpora: 5.4% (-0.2%)
- Capital Internationa: 3.6% (+1.5%)
- Capital World Invest: 3.5% (+11.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 3 raises (avg +10%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.01 suggests fair value with growth premium. Forward P/E 15.4x stretched relative to 3% growth. Quality metrics strong (ROE 82%, margin 20%). Balance sheet: $4.2B free cash flow. Analyst sentiment positive (3 raises, avg +10%). Insider selling cluster ($2.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $169.8B |
| Beta | 0.45 |
| 52W Range | $253.30 - $346.38 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.01 |
| Forward P/E | 15.4 |
| Current P/E | 15.9 |
| YoY Growth | 2.9% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -1.4% to -2.7% (-1.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.7pp (needs >3.0% for momentum thesis). Underperforming sector by 4.1pp, stock-specific weakness. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.57), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.73% (CS: 17) | Weak |
| RSI_14 | 61.3 | Neutral |
| MACD Histogram | -0.57 | Bearish |
| vs SMA20 | 1.019x | Above |
| vs SMA50 | 1.098x | Above |
| vs SMA200 | 1.141x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $337.49
- **Stop Loss:** $322.39 (4.5% risk)
- **Target:** $352.59 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 49
- **Position Value:** $16,537.01
- **Portfolio %:** 16.54%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-03 (Est: $4.74)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.01 | $5.64 | +12.5% |
| 2025Q2 | $5.28 | $6.02 | +14.1% |
| 2025Q1 | $4.26 | $4.90 | +15.0% |
| 2024Q4 | $5.08 | $5.31 | +4.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*